Overview of the current role of stereotactic body radiotherapy in the treatment of unfavorable intermediate- and high-risk prostate cancer.

Maris Mezeckis, Vesprini Danny, Buryk Vladyslav, Miszczyk Leszek, Vjaters Egils

Abstract read

In one paragraph

Article in Journal of radiosurgery and SBRT, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maris MezeckisUniversity of Latvia, Sigulda Hospital Centre of Stereotactic Radiosurgery, Lakstigalas str. 13, Sigulda, LV-2150, Latvia, EU.

Vesprini DannyUniversity of Toronto, Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, T-wing 2075 Bayview Avenue TG 260, Toronto, ON, M4N 3M5, Canada.

Buryk VladyslavSigulda Hospital Centre of Stereotactic Radiosurgery, Lakstigalas str. 13, Sigulda, LV-2150, Latvia, EU.

Miszczyk LeszekRadiotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice, Wybrzez˙e Armii Krajowej 15, 44-102 Gliwice, Poland, EU.

Vjaters EgilsUniversity of Latvia, P.Stradins Clinical University Hospital, Centre of Urology, Pilsonu str. 13, Riga, LV-1002, Latvia, EU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stereotactic body radiotherapy (SBRT) is well accepted for low- and intermediate-favorable risk prostate cancer. Available evidence about the application of SBRT in unfavorable- and high-risk prostate cancer is less solid. During last year's multiple variations in treatment, techniques have been reported making comparisons more complicated. This review's objective is to review current evidence in application of SBRT in intermediate unfavourable and high-risk prostate cancer and to outline variations in SBRT treatment techniques and relevant results.

Indexed as

high-risk prostate cancerIntermediate unfavorableSBRTstereotactic body radiotherapy

Identifiers

PMID36275129

PMCPMC9489076

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.